‘GLP-1s, should we all be taking them?’



Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

From diabetes breakthrough to longevity lightning rod, GLP-1s are reshaping metabolism, policy and the meaning of prevention.

The debut episode of Longevity.Technology UNLOCKED drops today.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Phil Newman

Phil Newman is the Founder and CEO of Longevity.Technology. In 2018 he saw an opportunity in the emerging longevity field to create this media and market intelligence platform that addressed the science, business and investment of the field.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Evommune bets $30m upfront on a new autoimmune drug

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE